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BIOLOGY OF EPSTEIN-BARR VIRUS INFECTION IN VIVO
The Epstein-Barr virus (EBV), a ubiquitous human
gammaherpesvirus, infects more than 90% of humans and
persists in the host for life. The EBV genome consists of a
linear double-stranded DNA of 172 kbps encoding almost
100 viral genes that are expressed in different tightly regu-
lated blocks in different forms of latent infection as well as
during lytic infection of host cells both in vitro and in vivo
[1] (Table 1).
Primary and Persistent EBV Infection
Primary infections occurring in early childhood are usu-
ally asymptomatic or have nonspecific symptoms. In con-
trast, primary EBV infections of adolescents and young
adults often lead to infectious mononucleosis, a self-limiting
lymphoproliferative disease characterized by fever, lym-
phadenopathy, and pharyngitis. EBV infects humans by
entering the oropharynx in saliva and then either replicating
in epithelial cells, with subsequent infection of B cells that
inﬁltrate oropharyngeal tissue [2], or infecting B cells of the
oropharynx directly [3]. Alternatively, EBV can be transmit-
ted via blood products, so that after allogeneic hematopoietic
stem cell transplantation (HSCT), the donor EB virus strain
becomes dominant in the recipient [4]. During primary
infection, EBV-infected B cells in peripheral blood express
a pattern of latent genes (latency III) that drives lympho-
proliferation. These cells are positive for the EBV nuclear
antigens (EBNAs) 1, 2, 3a, 3b, 3c, and LP and for the latent
membrane proteins (LMPs) 1, 2a, and 2b, as well as for
2 untranslated RNAs (EBV encoded small RNAs [EBERs]
1 and 2) [5]. This gene expression pattern is also found in
lymphoblastoid cell lines (LCLs) transformed by EBV in
vitro. Among these latent EBV genes, EBNA1 binds to viral
DNA and is responsible for the maintenance of EBV epi-
somes in replicating host B cells. EBNA2 upregulates cellu-
lar proteins contributing to the growth and transformation
of B cells [1]. LMP1 mimics a ligand-independent, constitu-
tively active form of the molecule CD40 and leads to activa-
tion of nuclear factor-κB (NF-κB) transcription factor,
resulting in cytokine production and B-cell proliferation [6].
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ABSTRACT
Uncontrolled expansion of donor-derived Epstein-Barr virus (EBV)-infected B cells has become a significant prob-
lem in recipients of allogeneic hematopoietic stem cell transplantations. Major risk factors for the early develop-
ment of posttransplantation lymphoproliferative disease include the use of unrelated or HLA-mismatched related
donors, selective T-cell depletion of donor marrow, and the use of antithymocyte globulin or monoclonal anti–T-cell
antibodies for the prophylaxis and treatment of acute graft-versus-host disease. Over the past few years, the admin-
istration of in vitro–generated EBV-specific cytotoxic T cells or anti–B-cell monoclonal antibodies has provided
effective options for the prophylaxis or treatment of posttransplantation lymphoproliferative disease. Advances in
quantitative polymerase chain reaction–based assays allow both the precise measurement of EBV load in peripheral
blood samples and the identification of high-risk patients for early initiation of therapy. A major remaining challenge
is to assess the significance of an elevated EBV load posttransplantation and to determine the indications for pre-
emptive treatment.
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LMP2a affects B-cell receptor (BCR) signaling by mimicking
the rescue signal delivered by this receptor. Thus, LMP2a
allows nontransformed B cells to survive without appropriate
BCR signaling [7]. As a consequence of EBV-driven lympho-
proliferation during acute EBV infection, up to 1% of total
peripheral B cells are latently infected with EBV (latency
III). In a small proportion of latently infected B cells, EBV
eventually undergoes lytic replication [8], leading to cell-free
viremia in peripheral blood [9]. B cells either transformed by
EBV or containing replicating virus are highly immunogenic
and provoke a vigorous and effective cytotoxic T lymphocyte
(CTL) and natural killer cell response [10]. Although most
EBV-infected B cells are eliminated during the convales-
cence of acute infection, some persist due to mechanisms
that allow the cells to avoid immune recognition, such as
down-regulation of immunogenic EBV proteins. Thus, dur-
ing persistent EBV infection, an equilibrium is established in
which rare EBV-infected B cells lacking expression of
immunogenic EBV-proteins coexist with EBV-specific
CTLs. Approximately 1 to 50 EBV-infected cells are found
per 1 × 106 peripheral B cells in persistent carriers [11,12].
These EBV-infected cells express only LMP2a and the
EBERs as well as possibly EBNA1 (silent infection or latency
0) [13,14]. In healthy carriers, EBV undergoes lytic replica-
tion in some B cells of the oropharynx, leading to the shed-
ding of virus into the saliva or to infection of epithelial cells
with subsequent release of virus. Thus, in nearly every
healthy carrier, infectious EB virions can be detected in saliva
samples [15] (Figure).
EBV Infection in Immunosuppressed Patients
In immunosuppressed patients, immune surveillance
may be unable to control the proliferation and outgrowth of
EBV-infected B cells, as is often seen after primary EBV
infection or after reactivation of persistent EBV infection.
In HSCT recipients, the source of EBV-driven lymphopro-
liferation is usually the donor-derived EBV-infected B cells
transmitted by the graft. Whereas in asymptomatic trans-
plant recipients, EBV-infected peripheral B cells express a
restricted pattern of EBV genes (latency 0), a transformation-
associated growth program of EBV gene expression has
been consistently observed in peripheral blood and affected
lymphoid tissues of patients with posttransplantation lym-
phoproliferative disease (PTLD) [16]. Additionally, some of
the EBV-infected cells in PTLD patients appear to undergo
lytic replication [17].
CHARACTERISTICS OF PTLD AFTER BONE MARROW
TRANSPLANTATION
Although HSCT is now widely accepted as therapy for
hematologic malignancies, solid tumors, and certain nonma-
lignant disorders, neoplastic diseases are emerging as a seri-
ous complication in long-term survivors who have received
this treatment. The risk of cancer induction in HSCT recipi-
ents is 4- to 7-fold that in general populations. Moreover,
because of the profound immunodeﬁciency in the ﬁrst year
after transplantation, PTLD is the most common second
malignancy during that period. The cumulative incidence of
PTLD in allogeneic HSCT recipients is 1.0% (range, 0.5%-
1.8% in reports from single institutions) [18,19]. Its occur-
rence is highest during the first 5 months post-HSCT
(210 cases/10,000 patients per year), declining to fewer than
5 cases/10,000 patients per year after the ﬁrst year posttreat-
ment. The vast majority of early-onset PTLD cases (≤1 year
posttransplantation) are EBV associated. Major risk factors
for the early development of PTLD in allogeneic HSCT
recipients include the use of unrelated or HLA-mismatched
related donors (≥2 mismatches), T-cell depletion of donor
marrow, and use of antithymocyte globulin or monoclonal
anti–T-cell antibodies for the prophylaxis and treatment of
acute graft-versus-host disease (GVHD). The rate of PTLD
in patients with 2 major risk factors increases to approxi-
mately 8%. Patients with ≥3 risk factors have the highest
incidence of PTLD (22%) [18]. When a T cell–depleted
graft is used, the risk of PTLD can be reduced by employing
methods that additionally deplete B cells [20,21]. The only
risk factor for late-onset PTLD (>1 year post-HSCT) is
chronic GVHD, although such cases are less likely to be
associated with EBV infection. In rare cases, PTLD may
occur in autologous HSCT recipients. Of the 7 cases
reported to date, the development of PTLD may have
involved immunological depression by the underlying disease
or by long-standing treatment with chemotherapy [22,23].
Table 1. Patterns of EBV Gene Expression in Infected Peripheral B Cells In Vivo
Category Genes Expressed Associate Condition
Silent EBV infection (latency 0) (EBNA1) Healthy EBV-seropositive carriers
LMP2a
EBER
Growth program (latency III) EBNA1 Infectious mononucleosis
EBNA1 3a, 3b, 3c, -LP
LMP1, 2a, 2b
EBER
Lytic replication EBNA1 Infectious mononucleosis
EBNA1, 3a, 3b, 3c, -LP
LMP1, 2a, 2b
EBER
BZLF1, BMLF1, BRLF1
Early antigen, eg, EA
Late antigen, eg, viral capsid antigen (VCA)
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Because of its histologic and clinical heterogeneity
(Table 2), PTLD can be difﬁcult to diagnose. Clinically, it
may present as an infectious mononucleosis–like illness with
fatigue and lymphadenopathy or febrile illness with
leukopenia. Focal or disseminated lymphoproliferation may
involve the lymph nodes, liver, kidney, bone marrow, and
the central nervous system, as well as the small intestine
[24]. Often, diffuse illness is diagnosed only at autopsy in
patients thought to have fulminant sepsis or severe GVHD,
underscoring the need for a high index of suspicion when
making this diagnosis.
MONITORING OF PATIENTS AT RISK FOR THE
DEVELOPMENT OF PTLD
In the immunocompetent host, serology is still regarded
as the gold standard for confirming acute-versus-remote
EBV infection. However, after HSCT, patients have a pro-
longed period of humoral immunodeﬁciency, with an aver-
age of 3 months required for B cells to recover to normal
numbers in the peripheral blood. Moreover, many patients
have abnormal subpopulations of circulating B cells, as well
as oligoclonal or monoclonal gammopathies, for extended
times. EBV antibodies are also passively transmitted by
immunoglobulin therapy, which may signiﬁcantly alter sero-
logical results. Hence, EBV serology is not a reliable indica-
tor of the clinical status of transplantation patients. In our
experience, clinically relevant EBV infection is best detected
by direct testing of viral nucleic acids.
Polymerase chain reaction (PCR)-based assays have
become a valuable tool for measuring the EB viral load in
peripheral blood samples after HSCT. Such measurements
are powerful aids in the prediction and diagnosis of PTLD as
well as in the monitoring of treatment responses in these
patients. Our group initially showed that a 2- to 3-log
increase in EBV DNA isolated from peripheral blood
mononuclear cells (PBMC) after HSCT was highly predic-
tive for the development of PTLD after T cell–depleted
Model of primary and persistent EBV infection in humans. EBV infects humans by entering the oropharynx in saliva and then either replicating in
epithelial cells with subsequent infection of B cells that inﬁltrate oropharyngeal tissue [2] or directly infecting B cells of the oropharynx. Alternatively,
EBV can be transmitted via blood products, so that after allogeneic HSCT, the donor EBV strain becomes dominant in the recipient. During primary
infection, EBV-infected B cells in peripheral blood express a pattern of latent genes (latency III) that drives lymphoproliferation: These cells are posi-
tive for EBNA1, 2, 3a, 3b, 3c, and LP and for LMP1, 2a, and 2b, as well as for 2 untranslated RNAs (EBERs 1 and 2). This gene expression pattern is
also found in LCLs transformed by EBV in vitro. In a small proportion of latently infected B cells, EBV eventually undergoes lytic replication, lead-
ing to cell-free viremia in peripheral blood. B cells either transformed by EBV or containing replicating virus are highly immunogenic and provoke a
vigorous and effective CTL and NK cell response. Although most EBV-infected B cells are eliminated during the convalescence of acute infection,
some persist because of mechanisms that allow the cells to avoid immune recognition, such as down-regulation of immunogenic EBV proteins. Thus,
during persistent EBV infection, an equilibrium is established in which rare EBV-infected B cells lacking expression of immunogenic EBV proteins
coexist with EBV-speciﬁc CTLs. These EBV-infected cells express only LMP2a and the EBERs as well as possibly EBNA1 (silent infection or latency
0). In healthy carriers, EBV undergoes lytic replication in some B cells of the oropharynx, which leads to the shedding of virus into the saliva or to
infection of epithelial cells with subsequent release of virus. Thus, in nearly every healthy carrier, infectious EB virions can be detected in saliva sam-
ples. In immunosuppressed patients, immune surveillance may be unable to control the proliferation and outgrowth of EBV-infected B cells, as often
seen after primary EBV infection or after reactivation of persistent EBV infection. In HSCT recipients, the source of EBV-driven lymphoprolifera-
tion is usually the donor-derived EBV-infected B cells transmitted by the graft. Whereas in asymptomatic transplantation recipients, EBV-infected,
peripheral B cells express a restricted pattern of EBV genes (latency 0), a transformation-associated growth program of EBV gene expression has been
consistently observed in peripheral blood and affected lymphoid tissues of patients with PTLD.
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transplantation [25]. Successful treatment of this disease with
donor leukocytes or EBV-speciﬁc CTLs was accompanied by
a decrease in EBV load to undetectable levels [25,26]. Lucas
et al. [27] also reported increased levels of EBV DNA in the
whole blood leukocytes of patients with PTLD. In follow-up
examinations, 1 patient with complete remission showed a
decrease in the EBV load, whereas another patient with pro-
gressive disease had an increase in this measurement [27].
Hoshino and coworkers used real-time quantitative PCR
(RQ-PCR) analysis to demonstrate an excessive viral load in
2 HSCT recipients with PTLD, in comparison with a
decreased load during complete remission [28]. More
recently, a multicenter European study conﬁrmed the associ-
ation of elevated EBV DNA levels in patients with PTLD
following T-cell–depleted HSCT, but found that the recipi-
ents of unmanipulated grafts often had an increase in EBV-
DNA levels without developing lymphoproliferative disease
[29]. The data on viral load in HSCT recipients, with or
without PTLD, are summarized in Table 3.
Greater numbers of patients have been studied after
solid organ transplantation (SOT). A signiﬁcant increase in
EBV load in the peripheral blood of SOT patients was
demonstrated in several groups of patients during the devel-
opment of PTLD [30-36]. Moreover, a decrease of EBV
DNA was found in the peripheral blood of some of these
organ recipients during successful treatment and regression
of PTLD [30,34]. Despite these advances, we still lack
absolute measurements that are both sensitive and speciﬁc
predictors of PTLD in either HSCT or SOT recipients.
The variability of measurements in previous studies might
reflect differences in the methods and materials used to
quantify viral load: for example, comparative PCR assays
with end-point dilution [30] versus quantitative competitive
PCR assays [31,33,34] versus RQ-PCR assays [32,35,36] and
PBMC [30-32,36] versus whole blood [34] versus serum or
plasma samples [35]. Quantitative assays of EBV load should
be (1) highly sensitive, (2) sufﬁciently ﬂexible to allow detec-
tion of DNA of different natures, (3) reproducible, (4) fairly
precise, and (5) suitable for widespread routine application
(fast and safe, minimal handling) [37]. Real-time PCR-based
assays meet these criteria best [38]. In the studies mentioned
above, some measurements of an increased EBV load
detected with PBMC or whole blood that were highly sensi-
tive for the diagnosis of PTLD were not specific for this
diagnosis, as a signiﬁcant number of transplantation patients
showed similar or even higher amounts of viral load without
subsequent development of PTLD. Wagner and coauthors
found that RQ-PCR measurement of viral load in plasma
appeared to be more speciﬁc for the diagnosis of PTLD than
measurements in PBMC [39]. Moreover, the accuracy of
measurements in PBMC could be enhanced by normalizing
the detected EBV copy number toward the amount of coam-
pliﬁed genomic DNA by RQ-PCR [36]. Further compara-
tive studies are needed to address the question of which
material is best suited for EBV load measurements
(plasma/serum, PBMC, or whole blood). When plasma is
used as test material, one must take care to avoid PCR
inhibitory factors in heparinized samples, for instance by
using EDTA as an anticoagulant [32].
TREATMENT OF PTLD
Although the reduction of immunosuppressive therapy
has been effective in SOT recipients, it has not proved feasi-
ble after HSCT. Because of the pronounced endogenous
immunodeﬁciency accompanying HSCT, simple withdrawal
of immune suppression in such patients does not lead to
rapid immune recovery capable of eliminating proliferating
EBV-infected B cells. Anecdotal reports have described the
therapeutic option of using α-interferon plus intravenous
immune globulin in SOT and HSCT recipients with PTLD.
Chemotherapy and radiotherapy has also been shown to be
effective in treating PTLD in some SOT recipients, but this
therapeutic modality is often accompanied by severe toxicity
[40]. Hydroxyurea has also been shown to have anti-EBV
activity in vitro, and promising results were recently reported
in 2 patients with human immunodeficiency virus (HIV)-
related EBV-related primary central nervous system lymphoma
who received low-dose hydroxyurea [41].
Adoptive immunotherapy with unselected donor leuko-
cytes or donor-derived EBV-speciﬁc CTLs offers an effec-
tive treatment for patients who have undergone HSCT. In
one study, 17 of 19 patients with PTLD responded to ther-
apy with unselected donor T-cell infusions, but acute or
chronic GVHD developed in 3 and 8 patients, respectively
[42]. In another study, only 4 of 13 patients (31%) showed
regression of disease after treatment with donor T-cell infu-
sions, whereas the same proportion of patients (31%) experi-
enced GVHD [27]. One strategy to lower the potential risk
of GVHD is the use of in vitro–generated EBV-specific
CTLs rather than unmanipulated donor T cells. The pro-
phylactic administration of EBV-speciﬁc CTLs to patients at
high risk of developing PTLD has been shown to be both
effective and safe [26,43,44]. None of the patients treated by
this approach developed PTLD, compared with an incidence
of 11.5% in an untreated historical control group. Gene-
marked EBV-speciﬁc CTLs were detectable in the periph-
eral blood of patients for as long as 78 months [45]. In each
of 9 patients with an elevated EBV load who were given
EBV-specific CTLs as prophylaxis, the EBV-DNA copy
numbers rapidly decreased to normal levels with an increase
in EBV-specific cytotoxicity. Three patients who were not
treated prophylactically and developed PTLD subsequently
received EBV-specific CTLs. Two had either a complete
remission or stable disease [44], whereas the remaining
patient died of progressive disease 24 days after treatment. In
this child, the major cytolytic activity of the donor CTLs was
directed against 2 epitopes in the EBNA3B gene. Sequence
analysis of this gene revealed a 245–base pair deletion in the
Table 2. Histopathological Classiﬁcation of PTLD
I. Early lesions, infectious mononucleosis–like reactive plasma cell
hyperplasia
II. Polymorphic PTLD (monoclonal and polyclonal)
IIIa. Monomorphic PTLD (diffuse large-cell B-cell lymphoma:
immunoblastic, centroblastic, or anaplastic)
IIIb. Burkitt’s lymphoma
IV. T-cell lymphoma
V. Other, including Hodgkin’s lymphoma, plasmacytoma-like
lesions, multiple myeloma
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EBNA3B gene in the tumor virus, which removed these
2 target epitopes for CTL recognition [46]. Thus, escape
mutants may arise even when polyclonal CTLs are used for
the treatment of PTLD. A study from Sweden has recently
conﬁrmed the efﬁcacy of prophylactic EBV-speciﬁc CTLs in
reducing viral load in patients with high EBV levels after bone
marrow transplantation [47]. However, in 1 of the 6 patients,
the transferred line showed only weak EBV-speciﬁc activity,
and the patient subsequently developed PTLD.
CTLs appear most effective as prophylaxis or for the
treatment of minimal residual disease, because with fewer
tumor cells there is less chance of selecting escape mutants.
One limitation is that because PTLD requires immediate
treatment, CTLs must be available at diagnosis. The genera-
tion of EBV-speciﬁc CTLs requires 2 to 3 months, although
this time could be reduced by using EBV antigen–loaded
dendritic cells as antigen-presenting cells. Another strategy
recently described by Koehne et al. is to select virus-speciﬁc
cells early in culture by their susceptibility to transduction
with a retroviral vector [48]. Also, in certain clinical situa-
tions, CTL therapy may cause inﬂammation in patients with
bulky or infiltrative disease or may not persist in patients
receiving steroids at the time of treatment. If CTL therapy is
used prophylactically, recipients are only protected from 1 of
the many viruses that may cause morbidity and mortality
during the period of immunosuppression posttransplanta-
tion. Several groups have investigated approaches for modi-
fying the LCLs used as antigen-presenting cells to generate
multispeciﬁc CTLs. Transduction of LCL with a retroviral
vector encoding pp65 has allowed generation of CTLs spe-
ciﬁc for both CMV and EBV [49], whereas infection of LCL
with adenovirus results in generation of CTLs speciﬁc for
both adenovirus and EBV [50]. An alternative strategy to
generate broad antiviral immunity is to culture donor
mononuclear cells with recipient cells and then deplete pop-
ulations expressing activation markers, such as CD25, which
should contain alloreactive cells [51]. The residual allode-
pleted T-cell product will contain CTLs speciﬁc for multiple
viruses and potentially residual tumor cells.
Another intriguing option is the use of anti–B-cell anti-
bodies that eliminate B cells in vivo (Table 4). One study
tested murine monoclonal anti-CD24 and anti-CD21 anti-
bodies against PTLD in HSCT patients (n = 27) or SOT
patients (n = 31). Treatment was well tolerated, and com-
plete remissions were induced in 61% of PTLD episodes,
with an overall survival rate of 46% after a median follow-
up of 61 months. Risk factors for a partial or no response to
treatment included multivisceral disease, central nervous
system involvement, and late-onset PTLD. Overall, the long-
term survival rate was lower in patients undergoing HSCT
(35%) than in those undergoing SOT (55%) [52]. Several
studies tested the genetically engineered, humanized
chimeric monoclonal antibody Rituximab (Genentech, San
Francisco, CA; IDEC Pharmaceuticals, San Diego, CA),
which is directed against the B-cell surface marker CD20.
All 5 HSCT patients with PTLD who were treated in
2 studies entered complete remission, which was accompa-
nied by a normalization of EBV load in peripheral blood
[53,54]. Using CD20 antibody, another study reported com-
plete remissions in 5 of 6 HSCT patients with PTLD [55].
CD20 antibody was also used in 2 patients with risingTa
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EBV-DNA levels after treatment of GVHD with human-
ized CD3 antibody. In both cases, EBV-DNA levels became
undetectable, and neither patient developed PTLD [56].
HOW MIGHT PCR ASSAYS FOR EBV LOAD BE USED TO
GUIDE PREEMPTIVE TREATMENT?
Given that effective therapies are available for PTLD,
the challenge now is to determine how to use monitoring
tests to diagnose this complication early and to identify the
patients requiring preemptive treatment. It is obviously
preferable to treat patients with early or incipient disease,
because treatment of bulky disease is associated with signiﬁ-
cant morbidity [27,44,57] and a higher likelihood of gener-
ating escape mutants [46]. There are also potential hazards
with the available modalities. Donor T cells carry the risk of
inducing GVHD, whereas Rituximab produces profound
B-cell depletion and may further exacerbate immunodefi-
ciency in transplant recipients, although this effect is likely
to be transient, as CD20 is not expressed on B-cell precur-
sors or mature B cells. Initial concerns were that a lack of
EBV-infected B cells might impede recovery of EBV-speciﬁc
immunity, allowing the development of lymphomas later in
the posttransplantation course, and that depletion of the
B-cell reservoir of EBV would lead to infections in the
future. However, this has not been a problem in the patients
who received Rituximab at our institute. Finally, CD20
therapy may result in selection of a CD20-negative popula-
tion of proliferating B cells [58].
In our experience, an elevation of EBV-DNA to greater
than 4000 copies/µg on 2 consecutive occasions is associated
with a high risk for progression to PTLD in recipients of
T cell–depleted transplants [25]. However, some recipients
of non–T cell–depleted grafts show posttransplantation ele-
vations of EBV load to levels greater than 4000 EBV-copies/µg
PBMC DNA, without progression to PTLD [59]. Similar
results were obtained in a multicenter study in Europe [29].
These findings likely reflect the ability of the patients to
mount an immune response to EBV. The ability to identify
patients who can mount an immune response and therefore
do not require anti-EBV therapy would greatly aid the man-
agement of PTLD. We are currently developing an enzyme-
linked immunospot (ELISPOT) assay for this purpose.
At present, it seems reasonable to introduce preemptive
treatment in patients with high EBV load and a strong likeli-
hood of PTLD, such as recipients of T cell–depleted trans-
plants or patients who have received anti–T-cell antibodies in
vivo for GVHD. In lower-risk patients with high EBV-DNA
levels but no evidence of PTLD, the possible adverse effects
of CD20 antibody or T-cell therapy must be balanced
against the risk of developing lymphoproliferative disease.
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